

? ds

Set	Items	Description
-----	-------	-------------

S1	53	HEMOLYSIN AND (FUNGUS OR FUNGAL OR STACHYBOTRYS OR CANDIDA
----	----	--

OR ASPERGILLUS OR PENICILLIUM) AND ANTIBOD?

S2	35	RD S1 (unique items)
----	----	----------------------

S3	29	HEMOLYSIN AND (ALBICANS OR CHARTARUM OR FUMIGATUS OR CHRYS-
----	----	---

OGENUM) AND ANTIBOD?

S4	11	S3 NOT S2
----	----	-----------

S5 5 RD S4 (unique items)
S6 307 HEMOLYSIN AND (ALBICANS OR CHARTARUM OR FUMIGATUS OR
CHRY-

OGENUM)

S7 112 RD S6 (unique items)

S8 96 S7 NOT (S2 OR S3)

? logoff y

09jun03 09:27:22 User226352 Session D705.3

\$1.91 0.341 DialUnits File5

\$43.75 25 Type(s) in Format 7

\$43.75 25 Types

\$45.66 Estimated cost File5

\$0.33 0.056 DialUnits File6

\$3.80 2 Type(s) in Format 7

\$3.80 2 Types

\$4.13 Estimated cost File6

\$5.43 0.293 DialUnits File34

\$5.35 1 Type(s) in Format 2

\$112.35 21 Type(s) in Format 7

\$117.70 22 Types

\$123.13 Estimated cost File34

\$0.31 0.044 DialUnits File40

\$0.31 Estimated cost File40

\$1.93 0.428 DialUnits File50

\$46.00 23 Type(s) in Format 7

\$46.00 23 Types

\$47.93 Estimated cost File50

\$0.18 0.048 DialUnits File65

\$0.18 Estimated cost File65

\$1.47 0.195 DialUnits File71

\$1.68 1 Type(s) in Format 7

\$1.68 1 Types

\$3.15 Estimated cost File71

\$3.62 0.392 DialUnits File73

\$17.85 7 Type(s) in Format 7

\$17.85 7 Types

\$21.47 Estimated cost File73

?s s10/2001
 87 S10
 285421 PY=2001
 S12 2 S10/2001
 ?s s10 not s12
 87 S10
 2 S12
 S13 85 S10 NOT S12
 ?s s13 and (antibod? or monoclonal? or polyclonal? or antiser? or immunoglob? or elisa or eliza or eia or eifla or assay?)
 85 S13
 571115 ANTIBOD?
 153903 MONOCLONAL?
 31604 POLYCLONAL?
 51815 ANTISER?
 117627 IMMUNOGLOB?
 40980 ELISA
 40 ELIZA
 4925 EIA
 0 EIFLA
 377827 ASSAY?
 S14 21 S13 AND (ANTIBOD? OR MONOCLONAL? OR POLYCLONAL? OR ANTISER? OR IMMUNOGLOB? OR ELISA OR ELIZA OR EIA OR EIFLA OR ASSAY?)
 ?t s14/9/all
 14/9/1
 DIALOG(R)File 155:MEDLINE(R)
 10773135 20095921 PMID: 10632060
 The comparison of characteristics between membrane-active antifungal peptide and its pseudopeptides.
 Oh JE; Hong SY; Lee KH
 Protein Chemistry Laboratory, Mogam Biotechnology Research Institute,
 Yongin-city, Kyunggi-Do, South Korea.
 Bioorganic & medicinal chemistry (ENGLAND) Nov 1999, 7 (11) p2509-15
 , ISSN 0968-0896 Journal Code: B38
 Languages: ENGLISH
 Document type: Journal Article
 Record type: Completed
 Subfile: INDEX MEDICUS
 By the introduction of various amide surrogates, novel pseudopeptides corresponding to a membrane active depsipeptide were synthesized and their native characteristics compared with that of the peptide. The pseudopeptides had more resistance to serum proteases than the peptide and similar antimicrobial activities to that of the peptide without hemolytic activity. The pseudopeptides like the peptide were active against current drug resistant fungi and pathogenic fungi isolated from patients, and also had a strong synergism with current antifungal drugs against Candida albicans. The leakage assay suggested that the pseudopeptides also acted on the lipid membrane of pathogenic cells. These results indicated that the novel pseudopeptides had advantages over the peptide as a candidate for a novel antifungal drug and backbone modifications can be a tool in the development of a novel antifungal agent from membrane-active peptides

isolated from natural sources or chemically synthesized.
 Tags: Support, Non-U.S. Gov't
 Descriptors: Antifungal Agents--pharmacology--PD; *Candida albicans
 --drug effects--DE; *Oligopeptides--pharmacology--PD; Antifungal Agents
 --chemistry--CH; Circular Dichroism; Drug Synergism; Half-Life; Hemolysis
 --drug effects--DE; Liposomes; Microbial Sensitivity Tests
 CAS Registry No.: 0 (Antifungal Agents); 0 (Liposomes); 0 (Oligopeptides); 0 (lysyl-lysyl-valyl-valyl--phenylalanyl-lysyl-valyl-lysyl-phenylalanyl-lysyl-lysine); 0 (lysyl-lysyl-valyl-valyl-phenylalanyl-lysyl-valyl-lysyl-phenylalanyl-lysine)
 Record Date Created: 20000214

14/9/2
 DIALOG(R)File 155:MEDLINE(R)

10149127 99268435 PMID: 10338113
 A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides.
 Helmerhorst EJ; Reijnders IM; van 't Hof W; Veerman EC; Nieuw Amerongen AV
 Academic Centre for Dentistry Amsterdam (ACTA),
 Department of Oral Biochemistry, Vrije Universiteit, The Netherlands.
 ej.helmerhorst.obc.acta@med.vu.nl
 FEBS letters (NETHERLANDS) Apr 23 1999, 449 (2-3) p105-10, ISSN 0014-5793 Journal Code: EUH
 Languages: ENGLISH
 Document type: Journal Article
 Record type: Completed
 Subfile: INDEX MEDICUS
 The hemolytic and fungicidal activity of a number of cationic antimicrobial peptides was investigated. Histatins and magainins were inactive against human erythrocytes and Candida albicans cells in phosphate buffered saline, but displayed strong activity against both cell types when tested in 1 mM potassium phosphate buffer supplemented with 287 mM glucose. The HC50/IC50 ratio, indicative of the therapeutic index, was about 30 for all peptides tested. PGLa was most hemolytic (HC50 = 0.6 microM) and had the lowest therapeutic index (HC50/IC50 = 0.5). Susceptibility to hemolysis was shown to increase with storage duration of the erythrocytes and also significant differences were found between blood collected from different individuals. In this report, a sensitive assay is proposed for the testing of the hemolytic activities of cationic peptides. This assay detects subtle differences between peptides and allows the comparison between the hemolytic and fungicidal potency of cationic peptides.
 Tags: Animal; Comparative Study; Human; Support, Non-U.S. Gov't
 Descriptors: Antifungal Agents--pharmacology--PD; *Hemolysins
 --pharmacology--PD; *Peptides--pharmacology--PD; *Salivary Proteins
 --pharmacology--PD; Amino Acid Sequence; Candida albicans